

Orthocell key patents granted for Celgro™ and Ortho-ATI™

- Australian patent allowed for grant for method to manufacture Celgro™ soft tissue reconstructive, collagen based medical device
- Hong Kong patent granted for method to manufacture of Ortho-ATI™ for the regeneration of damaged tendons

Perth, Australia; 25 November 2015: Regenerative medicine company Orthocell Limited has today announced it has been granted key patents in Hong Kong and Australia covering the manufacture of human tenocytes to form the Ortho-ATI™ product and the manufacture of its collagen based soft tissue reconstructive medical device, Celgro™.

The patents are described as Hong Kong Patent No. 1179299 entitled “Culture medium, culturing method and use of tenocytes” and Australian patent no. PCT/AU2013/000621 entitled “Method for Producing a Collagen Membrane and Uses Thereof”.

Orthocell Managing Director Paul Anderson said: “The granting of these patents further strengthens our international IP position and complements already granted patents in the USA, Singapore, China and New Zealand. These patents provide a solid IP foundation for both our cellular therapy for tendon regeneration and for our collagen based medical device Celgro™ as we develop these for international markets.”

These patents relate to manufacture of novel bio-scaffolds to aid in the surgical repair of soft tissue injuries such as tendon, cartilage, bone and the delivery of cells to surgical sites and to the manufacture of Tenocyte cells the building blocks of human tendon. These patents form a solid foundation under our Ortho-ATI™ and Celgro™ products.

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au

Investor Relations

Ben Walsh
Buchan Consulting
P: 0468 422 865
E: bwalsh@buchanwe.com.au

Media enquiries

Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au

For personal use only

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

For personal use only